Department of Urology, University of Virginia

CorePlus Shows Success With Real-World Utilization of Ibex's AI Platform for Routine Cancer Diagnosis, Supporting Improved Patient Outcomes

Retrieved on: 
Dienstag, Oktober 10, 2023
Diagnosis, Triage, Professor, FACS, Hospital, Breast, AI, MD, Urology, Prostate, Marie Cassidy, Cancer, Ponce Health Sciences University, Laboratory, Entrepreneurship, Department of Urology, University of Virginia, Pathology, Prostate cancer, Malignancy, Patient, Medical device, Medical imaging, Ibex

BOSTON and CAROLINA, Puerto Rico, Oct. 10, 2023 /PRNewswire/ -- Ibex Medical Analytics (Ibex), the leader in AI-powered cancer diagnostics, and CorePlus Servicios Clínicos y Patológicos, LLC (CorePlus), a high complexity CLIA-certified clinical and anatomic pathology laboratory, today announced CorePlus has diagnosed over 10,000 cases using Galen™, Ibex's AI-powered cancer diagnostics platform. In a significant boost to patient outcomes, pathologists used AI-driven insights from Galen to correct the diagnosis of over 150 patients.

Key Points: 
  • In a significant boost to patient outcomes, pathologists used AI-driven insights from Galen to correct the diagnosis of over 150 patients.
  • Galen demonstrated outstanding outcomes across multiple clinical studies performed on various tissue types and diagnostic workflows1,2,3,4,5.
  • "I am delighted to see CorePlus leading the way in adoption, demonstrating how patient outcomes can be improved through the implementation of AI for primary diagnosis.
  • We remain focused on bringing our AI platform to labs around the world to help pathologists reach zero misdiagnoses in cancer, and CorePlus demonstrates how this is achievable."

Vesica Health Announces Publication of Study Demonstrating AssureDx Meaningfully Improves Identification of Hematuria Patients at High Risk for Bladder Cancer

Retrieved on: 
Montag, Oktober 9, 2023
OTX1, Probability, AUA, Physician, Department of Urology, University of Virginia, National Capital FreeNet, American Urological Association, TERT, Johns Hopkins University, DNA, Risk, AUC, Capital city, Microhematuria, Urology, Hematuria, Health, HEALTH, Cancer, Carcinoma, TWIST1, Alvin J. Siteman Cancer Center, HRAS, DNA methylation, European Urology, Medical school, Patient, Bladder cancer, FGFR3, Liquid biopsy, Risk assessment, Barnes-Jewish Hospital

The study titled "A Urine-based Genomic Assay Improves Risk Stratification for Patients with High-risk Hematuria Stratified According to the American Urological Association Guidelines" was published in the journal European Urology Oncology.

Key Points: 
  • The study titled "A Urine-based Genomic Assay Improves Risk Stratification for Patients with High-risk Hematuria Stratified According to the American Urological Association Guidelines" was published in the journal European Urology Oncology.
  • The study analyzed a prospectively collected cohort of 838 hematuria subjects previously tested by AssureDx.
  • Subjects were classified into the AUA risk categories for bladder cancer based on their sex, age, and type of hematuria, also known as urothelial carcinoma (UC).
  • "Publication of this pivotal study in a leading international urology journal, demonstrating AssureDx enhances the AUA Guidelines, underscores the importance of the test for risk stratification of hematuria patients and identification of those at increased risk for bladder cancer," stated Christopher Thibodeau, Chief Executive Officer of Vesica Health.

Seoul St. Mary's Hospital Found Red Ginseng Oil is Excellent for Improving Prostatic Hyperplasia

Retrieved on: 
Donnerstag, September 14, 2023
Korea Ginseng Corporation, Retention rate, Urine, BPH, KGC, International Prostate Symptom Score, Nocturia, Research, Multimedia, JUNG, Malignancy, Capsule, Professor, Patient, Hospital, Department of Urology, University of Virginia, Ageing, Benign prostatic hyperplasia, Dietary supplement, IPSS

SEOUL, South Korea, Sept. 14, 2023 /PRNewswire/ -- Red ginseng oil has been found to be a safe and effective solution for improving prostatic hyperplasia for the first time.

Key Points: 
  • SEOUL, South Korea, Sept. 14, 2023 /PRNewswire/ -- Red ginseng oil has been found to be a safe and effective solution for improving prostatic hyperplasia for the first time.
  • Led by Professor Kim Sae Woong from the Department of Urology at Seoul St. Mary's Hospital, in collaboration with the Korea Ginseng Corporation (KGC), this research's results indicate that the intake of red ginseng oil extracted from JUNG KWAN JANG's RXGIN can safely and effectively improve prostatic hyperplasia.
  • It turns out that, compared to a mere 3.7% improvement in the control group, the red ginseng oil group experienced a significant 50.5% improvement in the red ginseng oil group in IPSS.
  • Professor Kim explained, "We found that red ginseng oil not only significantly improves the symptoms of BPH but also enhances dysfunction, which are the side effects of existing BPH(Benign prostatic hyperplasia) treatments."

LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone Approved in Japan for the Treatment of BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer

Retrieved on: 
Donnerstag, August 24, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, MSD, Prednisolone, Department of Urology, University of Virginia, HRR, NHA, NR, CI, Aes, OS, Cancer, MRK, Prognosis, RPF, AstraZeneca, Merck & Co., Prednisone, Death, HIV disease progression rates, Patient, Prostate cancer, Risk, Anemia, Propel, European, Nausea, BRCA, Metastasis, FDA, ITT, NYSE, Urology, Safety, Fatigue, Pharmaceutical industry, EU, Merck

As previously reported, there was a statistically significant improvement in rPFS in the full intention-to-treat (ITT) population in the PROpel trial (n=796).

Key Points: 
  • As previously reported, there was a statistically significant improvement in rPFS in the full intention-to-treat (ITT) population in the PROpel trial (n=796).
  • In the ITT population, common adverse events (AEs) in patients who received LYNPARZA plus abi/pred were anemia (45.5%), nausea (28.1%) and fatigue (27.9%).
  • Despite various treatment options available, the prognosis for mCRPC remains poor, with limited treatment options for patients whose cancer progresses following initial treatment.
  • This combination is also approved in the U.S. for the treatment of adult patients with deleterious or suspected deleterious BRCAm mCRPC.

PROCEPT BioRobotics® Announces First Commercial Aquablation Therapy Procedures in Japan

Retrieved on: 
Dienstag, August 22, 2023
Surgeon, BPH, Department of Urology, University of Virginia, Prostate, Patient, Division, Health, Pharmaceutical industry, Aquablation therapy, Urology

REDWOOD CITY, Calif., Aug. 22, 2023 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ: PRCT) (“PROCEPT BioRobotics”), a global leader in surgical robotics, announced today that it has successfully completed the first commercial Aquablation® therapy procedures in Japan.

Key Points: 
  • REDWOOD CITY, Calif., Aug. 22, 2023 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ: PRCT) (“PROCEPT BioRobotics”), a global leader in surgical robotics, announced today that it has successfully completed the first commercial Aquablation® therapy procedures in Japan.
  • Completing the first commercial procedures in Japan represents another important milestone in PROCEPT BioRobotics’ global expansion, highlighting the growing acceptance and recognition of Aquablation therapy as a pioneering solution for BPH patients.
  • "We view Japan as a very promising market for the adoption of Aquablation therapy, which has a long history of adopting new, innovative technologies, while prioritizing patient outcomes.
  • Aquablation therapy represents a significant advancement in BPH treatment, and we are excited to now offer this innovative solution to our patients.”

EDAP Announces Reimbursement Approval in Switzerland for the Use of High-Intensity Focused Ultrasound (HIFU) in the Treatment of Prostate Cancer

Retrieved on: 
Mittwoch, Juli 26, 2023
University of Zurich, University, TMS, EDAP, League, DACH, Department of Urology, University of Virginia, League of European Research Universities, Teaching hospital, Hospital, Patient, Prostate cancer, Health insurance, Medical imaging, Urology

LYON, France, July 26, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that it has received reimbursement approval in Switzerland for the use of High-Intensity Focused Ultrasound (HIFU) in the treatment of prostate cancer. This reimbursement took effect on July 1, 2023.

Key Points: 
  • LYON, France, July 26, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that it has received reimbursement approval in Switzerland for the use of High-Intensity Focused Ultrasound (HIFU) in the treatment of prostate cancer.
  • "Receipt of appropriate reimbursement from the Swiss healthcare authorities is another acknowledgment of the growing, worldwide acceptance of HIFU as an effective treatment option for men diagnosed with prostate cancer,” remarked Ryan Rhodes, Chief Executive Officer of EDAP TMS.
  • Switzerland has many hospitals ranked amongst the best 250 in the world according to Newsweek’s “The World’s Best Hospitals 2023”.
  • Switzerland is also a member of the DACH market region (including Germany, Austria and Switzerland) with over 100 million total inhabitants.

The Inner Circle Acknowledges, Joe Littlejohn, Jr as a Top Pinnacle Professional for his contributions to the field of Medical Technology and Urology

Retrieved on: 
Freitag, Juni 16, 2023
Male, Telehealth, Society, Howard University Hospital, Paruresis, Neurogenic bladder dysfunction, Gland, University, National Medical Association, Test management, University of Connecticut Health Center, EMR, Health technology, Data collection, American Urological Association, Penn State Health Children's Hospital, Medicine, DEI, Privacy, Christianity, Assistant, Inner circle, American Board of Commissioners for Foreign Missions, Patient, Love, Specialization, Ureter, NewYork-Presbyterian Hospital, General surgery, Department of Urology, University of Virginia, HPI, University of Connecticut School of Medicine, Health, Hospital, System, Female, Prostate cancer, Nursing, Medical imaging, Urology

MECHANICSBURG, Pa., June 16, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Joe Littlejohn, Jr. is acknowledged as a Top Pinnacle Professional for his contributions to the field of Medical Technology and Urology.

Key Points: 
  • MECHANICSBURG, Pa., June 16, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Joe Littlejohn, Jr. is acknowledged as a Top Pinnacle Professional for his contributions to the field of Medical Technology and Urology.
  • According to the doctor, urology is the branch of medicine that focuses on surgical and medical diseases of the male and female urinary-tract system and the male reproductive organs.
  • Aside from his medical career, Dr. Littlejohn, Jr. serves as an Assistant Professor of Surgery within the Department of Urology at Penn State Health Milton S. Hershey Medical Center.
  • The doctor offers his services at Penn State Health Surgery Specialties (Hershey Pennsylvania) & Penn State Health Medical Group Camp Hill Specialties.

New Stanford Research Study Provides Further Evidence for Personalized Prostate Cancer Mapping Using Machine Learning

Retrieved on: 
Donnerstag, Juni 15, 2023
Prostate cancer, Stanford University School of Medicine, 3D, Health, Cancer, Quality of life, Research, Department of Urology, University of Virginia, Prostate, MRI, Standard of care, Patient, Urology, Physician, Artificial intelligence, Neoplasm, AI, FDA, Recurrence, Disease, Biopsy, Medical imaging

CULVER CITY, Calif., June 15, 2023 /PRNewswire/ -- Avenda Health, an AI healthcare company creating the future of personalized prostate cancer care, today announced the results of a new study, "Prediction and Visualization of Lesion Extent in Intermediate-Risk Prostate Cancer using Artificial Intelligence," published in the European Urology Open Science. Led by Stanford University School of Medicine's Department of Urology, researchers found that Avenda Health's artificial intelligence (AI) software Unfold AI™, was shown to be accurate and effective in identifying the extent of prostate cancer.  This could be helpful in reducing the likelihood that cancer could be missed and left behind during treatment. The study demonstrates considerable promise for the technology to aid in reducing cancer recurrence rates.

Key Points: 
  • CULVER CITY, Calif., June 15, 2023 /PRNewswire/ -- Avenda Health , an AI healthcare company creating the future of personalized prostate cancer care, today announced the results of a new study , "Prediction and Visualization of Lesion Extent in Intermediate-Risk Prostate Cancer using Artificial Intelligence," published in the European Urology Open Science.
  • "The prostate cancer space has seen little to no advancement in nearly 40 years, and we look forward to bringing this important information to more prostate cancer patients in the coming year."
  • "Our mission at Avenda Health has always been to bring personalized care to prostate cancer patients to improve quality of life.
  • Avenda Health's prostate cancer management platform, Unfold AI, received FDA clearance in late 2022, opening the door for more precise prostate cancer management using AI.

DxVx, won the governmental project to develop diagnostic sensor kit for adult diseases

Retrieved on: 
Freitag, Juni 9, 2023
Semiconductor, Industrial technology, Diabetes, Urine, Prostate cancer, Engineering, Department of Electrical and Electronic Engineering, University of Manchester, Internet of things, Glucose, Biotechnology, Korea University, Core (group theory), Organic compound, Ageing, Electronics, Bladder cancer, Energy, Biomarker, Hanyang University College of Engineering, Hypertension, Ministry, POCT, Hanyang University, Data analysis, Algorithm, MEMS, Diagnosis, Department of Urology, University of Virginia, AI, Electricity, Ministry of Trade, Industry and Energy, Medical device

The main task is 'Development of optical sensor system for early diagnosis of adult diseases based on biomarkers in urine', which is to discover biomarkers (biochemical substances such as volatile organic compounds and glucose) in urine for full-time monitoring and early diagnosis of various adult diseases such as diabetes and prostate cancer.

Key Points: 
  • The main task is 'Development of optical sensor system for early diagnosis of adult diseases based on biomarkers in urine', which is to discover biomarkers (biochemical substances such as volatile organic compounds and glucose) in urine for full-time monitoring and early diagnosis of various adult diseases such as diabetes and prostate cancer.
  • It also aims to develop an in vitro POCT (point-of-care device) capable of measuring various biomarkers by applying MEMS (microelectromechanical system) technology, optical technology, semiconductor technology for signal processing, and artificial intelligence analysis technology.
  • With winning of this project, Dx&Vx expects to further accelerate its total biohealthcare solution business.
  • The products to be developed in the future are expected to be utilized for various adult diseases such as diabetes, hypertension, prostate cancer, and bladder cancer, and will be presented in the form of a non-invasive 'POCT equipment and cartridges, a sensor system for early diagnosis of adult diseases'.

Prostatype Genomics appoints Professor Gerald Andriole as Chief Medical Officer

Retrieved on: 
Freitag, Mai 5, 2023
Society, Prostate cancer, Genomics, Brigham and Women's Hospital, Research, Lung, Thomas Jefferson University, Washington University in St. Louis, Harvard Medical School, National Cancer Institute, Committee, Johns Hopkins University, Patient, Physician, Alvin J. Siteman Cancer Center, Joint Task Force National Capital Region Medical, Washington University School of Medicine, Neoplasm, Department of Urology, University of Virginia, Hospital, Capital city, Distinguishing, Barnes-Jewish Hospital, Pharmaceutical industry, Nursing, Urology, MD

SOLNA, Sweden, May 5, 2023 /PRNewswire/ -- Prostatype Genomics AB announced today that Professor Gerald Andriole has been appointed as global Chief Medical Officer at Prostatype Genomics.

Key Points: 
  • SOLNA, Sweden, May 5, 2023 /PRNewswire/ -- Prostatype Genomics AB announced today that Professor Gerald Andriole has been appointed as global Chief Medical Officer at Prostatype Genomics.
  • With more than 35 years in urology, Professor Andriole brings a wealth of experience and expertise to Prostatype Genomics as the company works towards commercializing the Prostatype® test in the United States and globally.
  • Professor Andriole received his medical degree from Jefferson Medical College in Philadelphia, Pennsylvania.
  • Fredrik Persson CEO of Prostatype Genomics says "We are honored that Professor Andriole has decided to join Prostatype Genomics.